No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
161 |
4. Check minimum number of eventsNone |
161 |
5. Include endpointsNone |
161 |
6. Filter based on genotype QC (FinnGen only) |
141 |
Control definitions (FinnGen only)
- Control exclude
- D3_IMMUNEMECHANISM
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Other or unspecified immunodeficiency
based on the number of shared cases.
Similar with more cases:
- Other immunodeficiencies
- Immunodeficiencies
- Certain disorders involving the immune mechanism
- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 792 | 445 | 340 |
| Only index persons | 679 | 396 | 283 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 41.63 | 44.77 | 37.09 |
| Only index persons | 41.98 | 44.85 | 37.96 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 141 | 90 | 51 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.02 |
| Median age at first event (years) | 48.26 | 47.36 | 49.85 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 145
- Matched controls
- 1450
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D84.9
ICD-10 Finland
Immunodeficiency, unspecified
+∞
129.2
104
*
D84.8
ICD-10 Finland
Other specified immunodeficiencies
+∞
52.3
47
*
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
16.8
40.8
38
30
J01MA14
ATC
moxifloxacin; systemic
11.1
37.3
48
62
J32.0
ICD-10 Finland
Chronic maxillary sinusitis
10.5
35.9
48
65
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
14.2
35.2
36
33
TDM10
NOMESCO Finland
Puncture of maxillary antrum
14.6
34.9
35
31
J01MA12
ATC
levofloxacin; systemic
7.7
32.9
68
150
DMB20
NOMESCO Finland
Functional endoscopic opening of maxillary antrum
10.9
28.8
35
41
UGC12
NOMESCO Finland
Flexible bronchoscopy
12.0
27.8
31
32
J45.1
ICD-10 Finland
Nonallergic asthma
8.5
25.2
38
58
J06BA01
ATC
immunoglobulins, normal human, for extravascular adm.; systemic
+∞
23.6
22
*
J45.0
ICD-10 Finland
Predominantly allergic asthma
7.2
23.3
42
78
J45.9
ICD-10 Finland
Asthma, unspecified
5.7
23.1
61
163
D80.1
ICD-10 Finland
Nonfamilial hypogammaglobulinaemia
+∞
22.5
21
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
6.0
22.1
108
476
J18.9
ICD-10 Finland
Pneumonia, unspecified
5.3
21.5
66
199
H02AB07
ATC
prednisone; oral
6.1
20.6
45
100
120
Kela drug reimbursment
Hypogammaglobulinaemia
+∞
20.3
19
*
R03DC03
ATC
montelukast; oral
5.3
19.8
55
151
D80.9
ICD-10 Finland
Immunodeficiency with predominantly antibody defects, unspecified
+∞
19.2
18
*
UJF30
NOMESCO Finland
Ileoscopy through colon
6.5
19.1
37
73
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
4.9
18.7
57
168
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
24.0
18.5
26
13
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
8.3
18.5
27
39
UJF32
NOMESCO Finland
Coloscopy
4.8
18.4
61
192
ZX120
NOMESCO Finland
Intravenous
6.0
18.3
39
84
UDH02
NOMESCO Finland
Rhinopharyngoscopy
6.9
18.2
32
57
TPH04
NOMESCO Finland
Cathetrisation of vein
4.7
18.0
61
195
R03BB04
ATC
tiotropium bromide; inhalant
6.9
16.6
29
51
J01FF01
ATC
clindamycin; systemic
4.2
16.3
70
264
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
17.5
16.1
25
17
H02AB06
ATC
prednisolone; systemic
4.3
15.9
99
481
D80.3
ICD-10 Finland
Selective deficiency of immunoglobulin G [IgG] subclasses
+∞
15.9
15
*
XQ800
NOMESCO Finland
Prick test
5.9
15.9
33
69
6BA02, ,
NOMESCO Finland
178.5
15.8
16
*
R03AK06
ATC
salmeterol and fluticasone; inhalant
4.7
15.1
44
123
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
5.9
14.8
30
61
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
6.2
14.6
28
54
Z2221
NOMESCO Finland
Medical doctor
3.9
14.6
70
281
C01CA24
ATC
epinephrine; parenteral
6.0
14.5
29
58
WW200
NOMESCO Finland
Immunization
14.9
14.5
24
19
GD1AD
NOMESCO Finland
Thorax CT examination
7.7
14.5
22
33
Z01.8
ICD-10 Finland
Other specified special examinations
4.1
14.4
56
194
TGC00
NOMESCO Finland
Bronchial lavation
27.1
14.2
19
8
ZXD30
NOMESCO Finland
Difficulties in perfomrming procedure
6.8
14.0
24
41
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.6
13.9
41
115
A49.9
ICD-10 Finland
Bacterial infection, unspecified
5.4
13.8
31
69
A07AA02
ATC
nystatin; oral
7.2
13.7
22
35
J01MA02
ATC
ciprofloxacin; systemic
3.7
13.6
76
334
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
5.9
13.5
27
54
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.7
13.3
63
248
J01.0
ICD-10 Finland
Acute maxillary sinusitis
3.7
13.2
68
282
R03AK07
ATC
formoterol and budesonide; inhalant
3.9
12.8
51
178
D80.8
ICD-10 Finland
Other immunodeficiencies with predominantly antibody defects
+∞
12.7
12
*
D84.18
ICD-10 Finland
Other specified defect in the complement system
+∞
12.7
12
*
Z3226
NOMESCO Finland
Physiotherapist
3.8
12.1
50
178
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
6.5
11.9
21
37
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.4
11.7
70
315
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
9.4
11.7
24
30
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
4.7
11.4
30
76
J47
ICD-10 Finland
Bronchiectasis
27.6
11.4
15
6
R03AK08
ATC
formoterol and beclometasone; inhalant
10.2
11.3
22
25
J45
ICD-10 Finland
Asthma
4.5
11.2
31
82
DM1AD
NOMESCO Finland
CT of paranasal sinuses and face area
9.8
11.0
22
26
ZXE00
NOMESCO Finland
One hour or less
3.2
10.8
82
419
R50.9
ICD-10 Finland
Fever, unspecified
3.7
10.8
44
154
H02AB04
ATC
methylprednisolone; systemic
4.1
10.7
35
105
Z3231
NOMESCO Finland
Registered nurse
3.2
10.6
63
279
R03AC03
ATC
terbutaline; inhalant
4.0
10.4
35
107
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
3.7
10.2
40
136
D02AE01
ATC
carbamide; topical
5.8
10.2
20
39
J01FA06
ATC
roxithromycin; oral
3.1
10.1
77
390
R03AL02
ATC
salbutamol and ipratropium bromide; inhalant
43.3
10.1
12
*
ZXA05
NOMESCO Finland
Left side
3.3
10.0
50
198
R03BA02
ATC
budesonide; inhalant
3.4
9.8
45
169
WX002
NOMESCO Finland
Sedation and analgesia
3.4
9.8
44
163
R03AK04
ATC
salbutamol and sodium cromoglicate; inhalant
106.7
9.5
10
*
JN3BD
NOMESCO Finland
Extensive abdominal CT
4.3
9.2
27
74
XG410
NOMESCO Finland
Flow-volume spirometry
8.9
9.2
19
24
J32.4
ICD-10 Finland
Chronic pansinusitis
20.2
9.1
13
7
J01DA06
ATC
[U] cefuroxime
3.5
9.1
38
134
R03BA08
ATC
ciclesonide; inhalant
4.2
9.1
27
75
ZXD10
NOMESCO Finland
Scheduled procedure
2.9
8.9
72
371
Z31.5
ICD-10 Finland
Genetic counselling
4.4
8.8
24
62
A02BC03
ATC
lansoprazole; oral
3.0
8.7
55
248
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
4.6
8.6
22
54
XF400
NOMESCO Finland
ECG with 12 standard connections
3.5
8.5
35
122
R4110
NOMESCO Finland
Physiotherapy
2.9
8.4
60
287
D86.0
ICD-10 Finland
Sarcoidosis of lung
+∞
8.4
8
*
R03AC02
ATC
salbutamol; inhalant
3.1
8.4
107
693
J31.0
ICD-10 Finland
Chronic rhinitis
4.0
8.3
26
75
R03BA05
ATC
fluticasone; inhalant
3.0
8.2
46
193
R03BA01
ATC
beclometasone; inhalant
3.5
8.1
32
108
XW000
NOMESCO Finland
Bone marrow biopsy
9.3
8.1
16
19
R03DA04
ATC
theophylline; systemic, rectal
9.3
8.1
16
19
A02BC02
ATC
pantoprazole; systemic
3.1
7.9
110
735
Z2446
NOMESCO Finland
Social worker
4.2
7.8
23
63
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
3.7
7.7
27
84
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
4.2
7.7
22
59
ZXE20
NOMESCO Finland
More than three and less than five hours
3.3
7.6
33
118
R96
ICPC
Asthma
3.9
7.5
24
70
TGD04
NOMESCO Finland
Needle biopsy of the lungs in bronchoscopy
84.2
7.5
8
*
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.6
7.4
73
407
R03AC12
ATC
salmeterol; inhalant
7.3
7.4
17
26
D84.1
ICD-10 Finland
Defects in the complement system
+∞
7.3
7
*
D86.8
ICD-10 Finland
Sarcoidosis of other and combined sites
+∞
7.3
7
*
D84.19
ICD-10 Finland
Unspecified defect in the complement system
+∞
7.3
7
*
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
2.9
7.2
43
185
ZXA10
NOMESCO Finland
Bilateral
3.0
7.2
39
159
Z03.89
ICD-10 Finland
Observation for other suspected diseases and conditions
3.1
7.1
36
141
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
3.6
7.1
26
83
ZXE10
NOMESCO Finland
More than one and less than three hours
2.6
7.1
66
355
A02BA02
ATC
ranitidine; systemic
3.1
7.1
35
135
R06AE09
ATC
levocetirizine; oral
3.1
7.0
34
130
R06.0
ICD-10 Finland
Dyspnoea
2.7
7.0
53
258
J01EE02
ATC
sulfadiazine and trimethoprim; systemic
2.6
7.0
58
296
D72.8
ICD-10 Finland
Other specified disorders of white blood cells
42.1
6.8
8
*
R01AD09
ATC
mometasone; nasal
2.5
6.6
86
536
R01AD08
ATC
fluticasone; nasal
2.5
6.6
61
326
JN4BD
NOMESCO Finland
Extensive body CT
3.5
6.5
24
77
R03DC01
ATC
zafirlukast; oral
15.2
6.5
10
7
XG470
NOMESCO Finland
Measurement of diffusion capastity of the lungs
8.8
6.5
13
16
C03CA01
ATC
furosemide; systemic
2.7
6.5
43
195
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
3.4
6.4
25
83
J02AC01
ATC
fluconazole; systemic
2.4
6.4
74
435
J46
ICD-10 Finland
Status asthmaticus
9.9
6.4
12
13
R10.1
ICD-10 Finland
Pain localized to upper abdomen
2.8
6.4
40
176
J84.8
ICD-10 Finland
Other specified interstitial pulmonary diseases
19.0
6.3
9
5
GCA98
NOMESCO Finland
Other bronchoscopic procedure on bronchus
19.0
6.3
9
5
D83.0
ICD-10 Finland
Common variable immunodeficiency with predominant abnormalities of B-cell numbers and function
+∞
6.3
6
*
D89.89
ICD-10 Finland
Other specified disorders involving the immune mechanism, not elsewhere classified
+∞
6.3
6
*
Y83
ICD-10 Finland
Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
4.0
6.3
19
53
J01FA09
ATC
clarithromycin; systemic
2.5
6.3
60
324
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
2.5
6.1
98
662
K07.60
ICD-10 Finland
Snapping jaw
3.9
6.1
19
54
J45.8
ICD-10 Finland
Mixed asthma
7.8
6.1
13
18
R06AX22
ATC
ebastine; oral
2.8
6.1
37
160
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
54
10
85.45
98.67
3.1
1.3
—
—
—
0
0
47
15
45.88
74.99
2.7
1.3
189.13
168.10
e6/l
—
40
10
45
16
40.33
69.31
2.8
1.3
605.03
596.50
e6/l
—
37
10
36
8
59.02
31.38
4.5
1.3
536.28
816.38
u/ml
—
36
8
59
130
6.97
28.07
2.5
1.6
—
—
—
0
0
68
174
6.48
27.64
3.2
1.7
—
—
—
0
0
31
33
11.68
27.20
5.8
2.4
—
—
—
0
0
56
124
6.73
26.34
2.9
1.6
—
—
—
0
0
30
13
28.67
22.38
2.1
1.6
0.85
0.58
e9/l
0.98
30
13
41
85
6.33
20.18
2.9
1.4
—
—
—
0
0
132
762
9.17
17.92
25.3
10.8
3.99
3.98
e9/l
0.01
127
669
24
33
8.52
17.08
3.4
1.5
—
—
—
0
0
41
104
5.10
15.90
6.7
8.3
0.55
1.43
mmol/l
0.62
33
86
57
198
4.10
14.62
4.0
2.5
2.25
2.42
g/l
1.23
52
179
13
0
+∞
13.76
2.2
0.0
0.89
—
iu/ml
—
8
0
24
29
9.69
11.88
2.6
1.3
—
—
—
0
0
22
23
11.06
11.74
2.1
1.3
—
—
—
0
0
24
30
9.36
11.65
3.5
1.6
—
—
—
0
0
17
10
19.04
11.51
2.7
1.5
—
—
—
0
0
25
58
5.00
10.53
2.4
1.6
—
—
—
0
0
43
154
3.55
10.12
7.2
7.3
105.51
104.45
mmol/l
0.90
43
154
19
22
9.76
9.64
2.9
1.3
—
—
—
0
0
97
574
3.08
9.42
5.0
2.9
74.68
77.77
nmol/l
0.61
92
520
50
206
3.18
9.31
4.5
3.4
1.25
2.65
e6/l
0.96
28
100
85
471
2.94
9.27
8.2
3.3
28.25
30.61
u/l
0.63
85
447
16
15
11.83
9.05
2.1
1.4
—
—
—
0
0
19
26
8.24
8.78
1.8
1.2
—
—
—
0
0
18
23
8.77
8.67
2.1
1.4
—
—
—
0
0
31
103
3.56
8.05
3.0
1.5
—
—
—
0
0
14
13
11.77
7.99
9.7
5.1
—
—
—
0
0
69
368
2.67
7.72
5.8
3.3
0.14
0.42
e6/l
1.60
52
268
51
234
2.82
7.65
4.4
3.1
777.13
207.15
ng/l
0.49
30
162
21
57
4.14
7.21
2.1
1.7
—
—
—
0
0
13
13
10.85
7.20
3.1
1.2
—
—
—
0
0
49
228
2.74
7.08
4.1
3.1
1.13
0.77
e6/l
0.22
28
120
21
59
3.99
6.88
3.5
1.2
42.57
41.73
u/l
0.06
21
49
10
6
17.75
6.85
1.8
1.3
—
—
—
0
0
60
318
2.51
6.58
4.4
3.8
1649.64
945.69
ng/l
0.74
53
264
12
13
9.94
6.42
3.3
1.1
—
—
—
0
0
54
276
2.52
6.36
2.4
2.2
0.67
1.35
mg/l
1.25
48
221
14
22
6.92
6.03
1.1
1.5
—
—
—
0
0
14
22
6.92
6.03
1.1
1.5
—
—
—
0
0
17
35
5.36
5.97
2.1
1.5
1.67
0.01
iu/ml
—
6
6
13
19
7.40
5.88
3.2
1.5
—
—
—
0
0
15
27
6.07
5.87
2.0
1.5
—
—
—
0
0
20
62
3.58
5.69
1.8
1.3
—
—
—
0
0
11
13
9.05
5.67
3.9
1.8
—
—
—
0
0
8
5
16.80
5.47
1.0
2.4
12.94
11.20
umol/l
—
8
5
13
22
6.38
5.36
1.4
1.0
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
14
27
5.62
5.24
2.8
7.0
0.23
0.39
iu/ml
—
8
17
81
528
2.21
5.18
2.5
2.0
92.24
101.86
pmol/l
1.43
52
252
11
17
6.90
4.87
4.0
1.6
—
—
—
0
0
14
33
4.58
4.46
2.2
1.5
—
—
—
0
0
18
62
3.17
4.35
10.5
10.4
1.29
1.25
%
0.08
18
62
18
62
3.17
4.35
10.9
10.3
0.66
0.63
%
0.12
18
62
14
34
4.44
4.34
1.6
1.4
—
—
—
0
0
14
34
4.44
4.34
2.2
2.1
—
—
—
0
0
11
21
5.57
4.23
1.2
1.3
—
—
—
0
0
14
35
4.31
4.23
1.9
1.8
—
—
—
0
0
115
910
2.27
3.97
5.3
3.6
—
—
—
0
0
9
15
6.32
3.88
2.4
1.1
—
—
—
0
0
13
35
3.98
3.70
1.6
1.9
286.29
141.60
u/ml
—
7
20
7
9
8.10
3.60
2.9
1.2
—
—
—
0
0
51
311
1.99
3.59
3.4
2.4
—
—
—
0
0
6
6
10.36
3.53
1.2
1.0
—
—
—
0
0
13
43
3.22
3.34
1.8
2.6
4.86
3.20
index
—
7
25
13
39
3.56
3.32
1.5
1.9
—
—
—
0
0
6
7
8.87
3.29
1.3
3.1
—
—
—
0
0
6
7
8.87
3.29
1.3
3.1
—
—
—
0
0
13
40
3.47
3.24
1.5
1.3
—
—
—
0
0
14
50
2.99
3.19
1.2
1.4
—
—
—
0
0
83
614
1.82
3.11
4.2
2.8
—
—
estimate
—
0
0
140
1276
3.82
3.09
53.9
14.3
23.10
21.01
mg/l
0.37
126
1020
7
12
6.07
3.06
2.9
1.0
—
—
—
0
0
7
12
6.07
3.06
2.9
1.0
—
—
—
0
0
5
5
10.29
3.00
3.0
1.0
—
—
—
0
0
19
85
2.42
2.85
4.1
5.9
24.27
24.35
mmol/l
0.05
19
85
91
703
1.79
2.85
6.2
3.8
0.00
0.00
estimate
-0.00
19
148
22
106
2.27
2.81
8.0
3.7
—
—
—
0
0
64
449
1.76
2.78
5.5
3.4
22.83
34.55
ng/l
0.64
42
285
5
6
8.57
2.77
1.2
1.2
17.40
8.45
u/l
—
5
6
5
6
8.57
2.77
1.2
1.2
52.20
61.35
u/l
—
5
6
49
318
1.82
2.76
2.0
1.7
—
—
—
0
0
10
29
3.62
2.75
5.7
3.1
14.12
9.76
pmol/l
—
10
29
10
29
3.62
2.75
1.1
1.1
—
—
—
0
0
6
10
6.20
2.72
1.0
1.0
—
—
—
0
0
22
109
2.20
2.63
1.6
1.3
54.46
178.24
u/ml
—
8
41
128
1116
2.25
2.61
55.9
18.0
13.93
13.51
%
2.06
128
1109
8
20
4.17
2.61
2.0
1.9
—
—
—
0
0
20
96
2.26
2.57
9.3
10.6
24.62
25.17
mmol/l
0.23
20
96
89
695
1.73
2.57
6.2
3.8
0.00
0.00
estimate
-0.00
19
147
5
7
7.34
2.57
2.4
2.9
—
—
—
0
0
5
7
7.34
2.57
1.0
1.0
—
—
—
0
0
90
709
1.71
2.48
6.2
3.9
0.00
0.00
estimate
-0.00
18
140
14
58
2.56
2.45
3.1
4.9
1.50
1.39
%
0.13
14
58
14
58
2.56
2.45
9.8
6.8
7.66
8.98
kpa
1.98
14
58
54
372
1.72
2.44
5.1
4.1
51.54
10.31
mg/mmol
1.12
34
232
5
8
6.42
2.39
1.2
2.1
3.14
3.69
mg/l
—
5
8
53
368
1.69
2.31
4.7
2.2
109.34
161.07
u/l
1.13
53
353
55
386
1.68
2.30
5.9
3.3
0.00
0.01
estimate
0.50
16
122
13
56
2.45
2.11
3.2
5.0
0.61
0.66
%
0.19
13
56
5
11
4.66
1.95
2.4
1.3
—
—
—
0
0
18
94
2.04
1.90
9.2
2.6
0.14
0.15
e6/l
0.04
18
89
5
12
4.27
1.84
1.8
1.1
—
—
—
0
0
7
23
3.14
1.82
5.6
2.2
15.04
16.07
%
—
7
23
7
24
3.01
1.74
1.4
1.1
—
—
—
0
0
5
14
3.66
1.63
1.0
1.1
—
—
—
0
0
13
65
2.10
1.54
1.7
1.6
230.83
271.88
miu/ml
—
6
35
39
278
1.55
1.46
1.6
1.3
21.53
30.63
iu/ml
0.38
13
87
49
377
1.45
1.26
1.4
1.4
1.34
1.55
u/ml
0.08
14
117
6
126
0.45
1.24
11.8
6.1
—
—
—
0
0
17
102
1.76
1.22
6.8
3.1
60.27
68.46
ml/min/173m2
0.32
11
46
36
262
1.50
1.22
1.6
1.3
1.05
7.01
u/ml
1.85
13
99
5
20
2.55
1.16
1.0
1.2
—
0.83
—
0
9
9
46
2.02
1.06
1.2
1.1
—
—
—
0
0
5
22
2.32
1.04
1.0
1.2
—
—
—
0
0
5
23
2.21
0.99
1.2
1.0
0.13
0.03
u/ml
—
5
11
8
42
1.96
0.90
5.4
2.0
—
—
—
0
0
62
525
1.32
0.85
6.7
3.6
0.00
0.00
estimate
-0.00
17
128
124
1163
1.46
0.82
7.2
5.9
38.34
38.33
mmol/mol
0.00
119
1101
8
47
1.74
0.82
1.3
1.1
—
—
—
0
0
7
40
1.79
0.72
4.7
1.8
—
—
—
0
0
18
127
1.48
0.72
2.1
2.1
—
—
—
0
0
5
28
1.81
0.67
1.6
3.5
3.00
5.46
u/ml
—
5
28
38
311
1.30
0.65
6.4
3.6
1.02
1.02
kg/l
0.14
32
201
17
122
1.45
0.63
1.5
1.9
3.31
3.45
mmol/l
—
10
93
33
269
1.29
0.58
1.6
1.5
—
—
—
0
0
125
1192
1.35
0.56
5.9
4.7
5.73
5.80
mmol/l
0.29
120
1110
7
47
1.51
0.48
1.4
1.9
—
—
—
0
0
18
227
0.76
0.44
3.8
4.5
22.09
22.15
%
—
8
109
12
89
1.38
0.39
1.4
1.2
—
—
—
0
0
120
1238
0.82
0.33
5.1
4.9
1.44
1.48
mmol/l
0.44
110
1163
13
105
1.26
0.26
2.1
1.9
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
13.45
—
0
11
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
18
205
0.86
0.18
2.2
2.3
—
—
—
0
0
18
158
1.16
0.17
1.8
2.1
3.05
3.36
ratio
0.49
11
132
122
1243
0.88
0.16
5.1
5.0
4.66
4.65
mmol/l
0.02
114
1178
6
79
0.75
0.16
2.5
2.5
15.60
5.31
ug/l
—
6
70
36
384
0.92
0.13
8.0
3.8
0.00
0.00
estimate
-0.00
18
134
10
85
1.19
0.12
1.2
1.0
—
—
—
0
0
116
1181
0.91
0.12
4.4
4.1
1.48
1.24
mmol/l
2.07
104
1101
5
48
1.04
0.09
1.4
1.1
1.52
1.60
g/l
—
5
48
18
184
0.98
0.00
1.9
2.1
—
—
—
0
0
125
1252
0.99
0.00
5.8
5.6
2.73
2.74
mmol/l
0.04
113
1181
0
6
0.00
0.00
0.0
2.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
5
52
0.96
0.00
2.0
1.7
—
—
—
0
0
5
51
0.98
0.00
1.4
1.2
0.98
0.85
g/l
—
5
51
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
6
60
1.00
-0.00
1.3
1.7
43.12
52.71
ug/l
—
6
53
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
54
0.92
-0.00
1.4
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.9
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint D3_IMMUDEFNAS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| D3_IMMUDEFNAS | 3.678 [2.42, 5.58] | < 0.001 |
| Birth year | 0.989 [0.98, 1.0] | 0.021 |
During the follow-up period (1.1.1998 — 31.12.2019), 88 out of 387 females with D3_IMMUDEFNAS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| D3_IMMUDEFNAS | 2.774 [1.85, 4.16] | < 0.001 |
| Birth year | 0.986 [0.97, 1.0] | 0.025 |
During the follow-up period (1.1.1998 — 31.12.2019), 69 out of 289 males with D3_IMMUDEFNAS died.
Mortality risk
Mortality risk for people of age
years, who have D3_IMMUDEFNAS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.294% | 0.457% |
| 5 | 1.697% | 3.098% |
| 10 | 4.35% | 8.007% |
| 15 | 8.053% | 14.237% |
| 20 | 14.103% | 23.103% |
Relationships between endpoints
↥Index endpoint: D3_IMMUDEFNAS – Other or unspecified immunodeficiency
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data